Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

neurogenics

AI in Healthcare: How to Accelerate Change

Harry Glorikian, Author & General Partner at Scientia Ventures, dives into the current and future applications of AI and other innovative health technologies, including for personalized medicine, drug development, public...

Impetus Digital

- PMLiVE

Organon buys Forendo in $1bn deal

Forendo purchase bolsters Organon’s pipeline with candidates in endometriosis and polycystic ovarian syndrome

- PMLiVE

Merck’s $11.5bn acquisition of Acceleron delayed

Merck’s acquisition of Acceleron will take longer than expected as it refiles its paperwork, giving the FTC more time for review and itself more time to sell the deal to...

- PMLiVE

Merck’s COVID-19 antiviral under review in Europe by EMA

Molnupiravir could be the first oral antiviral treatment for COVID-19 in Europe for patients at risk of severe disease

Accelerating Drug Development Timelines with Big Data Analytics

Barış Erdoğan, CEO of Clinerion, shares how medical data informatics and real-world EHR data can be used to improve the efficiency and effectiveness of patient searches, identification, and recruitment; clinical...

Impetus Digital

Revolutionizing 3D Bioprinting & Disrupting the Drug Development Industry

Christine Whiteside, COO of VoxCell BioInnovation, discusses 3D bioprinting, including current and future applications and key barriers to realizing its full potential. She also shares her tips for getting new...

Impetus Digital

- PMLiVE

Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’

Sales grew by 19% in the second quarter as key products begin to recover from the impact of the pandemic

- PMLiVE

Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery

The FDA had previously rejected a supplemental biologics licence application in this indication

- PMLiVE

Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer

The FDA initially approved Keytruda in 2017 for stomach cancer based on overall response rate data

- PMLiVE

WHITE PAPER: From bench to bedside in one year – how the race for a COVID-19 vaccine will change the future of drug development

In this edition of MAGNIFI, we discuss the factors behind this acceleration in development of the COVID-19 vaccines and what this might mean for the future of pharma

IGNIFI

- PMLiVE

Positive results for AZ, Merck & Co’s Lynparza in early breast cancer presented at ASCO

Lynparza reduced the risk of invasive breast cancer recurrence, second cancers or death by 42% in the overall trial population

- PMLiVE

Merck & Co spinoff Organon launches with the aim of ‘improving health outcomes for women’

Merck & Co – known as MSD outside the US and Canada – announced its plans for the women’s health spinoff company last month

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links